Abstract:Background HIV and HCV infections have become the leading global public-health threats. Even more remarkable, HIV-HCV co-infection is rapidly emerging as a major cause of morbidity and mortality throughout the world, due to the common rapid mutation characteristics of the two viruses as well as their similar complex influence to immunology system. Although considerable progresses have been made on the study of the infection of HIV and HCV respectively, few researches have been conducted on the investigation of the molecular mechanism of their co-infection and designing of the multi-target co-inhibitors for the two viruses simultaneously. Results In our study, a multi-target Quantitative Structure-Activity Relationship (QSAR) study of the inhibitors for HIV-HCV co-infection were addressed with an in-silico machine learning technique, i.e. multi-task learning, to help to guide the co-inhibitor design. Firstly, an integrated dataset with 3 HIV inhibitor subsets targeted on protease, integrase and reverse transcriptase respectively, together with another 6 subsets of 2 HCV inhibitors targeted on NS3 serine protease and NS5B polymerase respectively were compiled. Secondly, an efficient multi-target QSAR modelling of HIV-HCV co-inhibitors was performed by applying an accelerated gradient method based multi-task learning on the whole 9 datasets. Furthermore, by solving the L -1-infinity regularized optimization, the Drug-like index features for compound description were ranked according to their joint importance in multi-target QSAR modelling of HIV and HCV. Finally, a drug structure-activity simulation for investigating the relationships between compound structures and binding affinities was presented based on our multiple target analysis, which is then providing several novel clues for the design of multi-target HIV-HCV co-inhibitors with increasing likelihood of successful therapies on HIV, HCV and HIV-HCV co-infection. Conclusions The framework presented in our study provided an efficient way to identify and design inhibitors that simultaneously and selectively bind to multiple targets from multiple viruses with high affinity, and will definitely shed new lights on the future work of inhibitor synthesis for multi-target HIV, HCV, and HIV-HCV co-infection treatments.

Proposal and Evaluation of a New Norm Index-Based QSAR Model to Predict Pec 50 and Pcc 50 Activities of HEPT Derivatives

QSAR Research of Novel Tetrandrine Derivatives Against Human Hepatocellular Carcinoma.

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Activity prediction of hepatitis C virus NS5B polymerase inhibitors of pyridazinone derivatives

The index of ideality of correlation: QSAR studies of hepatitis C virus NS3/4A protease inhibitors using SMILES descriptors

Predicting Anti‐HIV‐1 Activities of HEPT‐analog Compounds by Using Support Vector Classification

Multi-target QSAR study in the analysis and design of HIV-1 inhibitors

Proteochemometric Modeling Of The Bioactivity Spectra Of Hiv-1 Protease Inhibitors By Introducing Protein-Ligand Interaction Fingerprint

Towards Cheminformatics-Based Estimation of Drug Therapeutic Index: Predicting the Protective Index of Anticonvulsants Using a New Quantitative Structure-Index Relationship Approach.

QSAR Studies on 1-Aryl-tetrahydroisoquinoline Analogs As Active Anti-HIV Agents Based on PSO-v-SVM

Quantitative Structure-Activity Relationships of Hiv-1 Integrase Inhibitors of Dkas

Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study

Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors Ⅱ 3D-QSAR Study on 6-(1-naphthylmethyl)substituted Thymines

Docking Field-Based QSAR and Pharmacophore Studies on the Substituted Pyrimidine Derivatives Targeting HIV-1 Reverse Transcriptase

Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening

Topological Indices and QSPR Modeling of New Antiviral Drugs for Cancer Treatment

Predictive Comparative QSAR Analysis Of As 5-Nitofuran-2-YL Derivatives Myco bacterium tuberculosis H37RV Inhibitors Bacterium Tuberculosis H37RV Inhibitors

QSAR Study of Carboxylic Acid Derivatives As HIV-1 Integrase Inhibitors

Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues.

Three Dimensional Quantitative Structure-activity Relationship of HEPT Analogues As HIV-1 Reverse Transcriptase Inhibitors

Elucidating the Inhibiting Mode of AHPBA Derivatives Against HIV-1 Protease and Building Predictive 3D-QSAR Models